Fatty liver disease (MASLD/MASH) trials in Spain

In Spain 30 Also abroad 367

30 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Barcelona, Madrid, Pontevedra, Sabadell, Santander, Sevilla, Tomelloso, Valencia, Zaragoza
Age
18 years to 75 years
People
360 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07631637 · EU 2026-525916-33-00
No phaseTaking people
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Where
Badalona, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Valencia, Zaragoza
Age
18 years to 100 years
People
150
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07683065
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Barcelona, Madrid, Majadahonda, Sabadell, Santander, Seville, Valencia
Age
18 years to 80 years
People
1,650 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06215716
Phase 3Not yet taking people in Spain
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Where
El Palmar, Sanlúcar de Barrameda, Valencia
Age
18 years and over
People
600 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07850063 · EU 2026-527091-88-00
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago De Compostela, Zaragoza
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santiago De Compostela
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
No phaseTaking people
Exercise for an Aging Liver (EXALIVER)
Where
Madrid
Age
40 years and over
People
40
Run by
Consorcio Centro de Investigación Biomédica en Red (CIBER)
See details and how to joinNCT07467512
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Where
Barcelona, Madrid, Sabadell, Santander, Sevilla, Valencia
Age
18 years and over
People
205 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Badalona, Barcelona, Córdoba, Madrid, Majadahonda, Pontevedra, Santander, Santiago de Compostela, Sevilla
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Almería, Badalona, Barcelona, Córdoba, Madrid, Pontevedra, Santander, Santiago de Compostela, Zaragoza
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Not yet taking people in Spain
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Alcorcón, Barcelona, Córdoba, León, Madrid, Sevilla, Tomelloso, Valencia
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Spain
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Alcorcón, Barcelona, Córdoba, León, Madrid, Sevilla, Tomelloso, Valencia
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Barcelona, Madrid, Majadahonda, Sabadell, Santander, Seville, Valencia
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra, Santander, Seville, Valencia
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
A Coruña, Alcorcón, Barcelona, Córdoba, Donostia, León, Madrid, Santander, Sevilla, Tomelloso, Valencia, Valladolid
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
Phase 4Taking people
Fibrosis Lessens After Metabolic Surgery
Where
Barcelona
Age
18 years to 75 years
People
120 worldwide
Run by
The Cleveland Clinic
See details and how to joinNCT06374875
No phaseNot yet taking people in Spain
Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Where
Málaga
Age
18 years to 75 years
People
200
Run by
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
See details and how to joinNCT07684248
No phaseTaking people
UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers
Where
Seville
Age
18 years and over
People
450 worldwide
Run by
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
See details and how to joinNCT07652151
No phaseTaking people
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
Where
Madrid
Age
50 years to 75 years
People
3,000
Run by
Hospital General Universitario Gregorio Marañon
See details and how to joinNCT07658755
No phaseTaking people
Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
Where
Barcelona
Age
20 years to 80 years
People
140
Run by
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
See details and how to joinNCT07652892
Phase 2Taking people
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
Where
Girona
Age
18 years to 75 years
People
60
Run by
AB Biotics, SA
See details and how to joinNCT07193927
No phaseNot yet taking people in Spain
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
Where
Barcelona
Age
18 years and over
People
7,720
Run by
Hospital Universitari Vall d'Hebron Research Institute
See details and how to joinNCT07430501
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Where
Barcelona, Madrid, Majadahonda, Sabadell, Santander, Sevilla, Valencia
Age
18 years and over
People
244 worldwide
Run by
Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00
Phase 2Taking people
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
Where
Barcelona
Age
18 years to 85 years
People
30
Run by
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
See details and how to joinNCT06599918
No phaseTaking people
Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study
Where
Barcelona
Age
18 years to 75 years
People
25
Run by
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
See details and how to joinNCT07188220